Unknown

Dataset Information

0

Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium.

ABSTRACT: Antibody-drug conjugates (ADCs) combine the cytotoxicity of small-molecule drugs with antibody targeting. Due to their precise and powerful effect, they have become a new hotspot and an important trend in the research and development of anti-tumor antibody drugs. Every year, exciting new developments and innovations in the treatment of urological tumors are introduced at the American Society of Clinical Oncology-Genitourinary (ASCO-GU) Cancers Symposium. In this article, we summarize some of the most impressive advances in new clinical trials and clinical data on ADCs in the 2023 ASCO-GU Cancers Symposium for the treatment of urothelial carcinoma.

SUBMITTER: Yu J 

PROVIDER: S-EPMC10385919 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium.

Yu Jiazheng J   Wu Siyu S   Li Rong R   Jiang Yuanhong Y   Zheng Jianyi J   Li Zeyu Z   Li Mingyang M   Xin Kerong K   Guan Xiaojiao X   Li Shijie S   Chen Xiaonan X  

Journal of hematology & oncology 20230728 1

Antibody-drug conjugates (ADCs) combine the cytotoxicity of small-molecule drugs with antibody targeting. Due to their precise and powerful effect, they have become a new hotspot and an important trend in the research and development of anti-tumor antibody drugs. Every year, exciting new developments and innovations in the treatment of urological tumors are introduced at the American Society of Clinical Oncology-Genitourinary (ASCO-GU) Cancers Symposium. In this article, we summarize some of the  ...[more]

Similar Datasets

Unknown Novel agents and clinical trials in castration-resistant prostate cancer: latest updates from 2023 ASCO-GU Cancers Symposium.
| S-EPMC10391859 | biostudies-literature
Unknown Genitourinary cancers updates: highlights from ASCO 2023.
| S-EPMC10662513 | biostudies-literature
Unknown CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting.
| S-EPMC10401875 | biostudies-literature
Unknown ASCO Gastrointestinal Cancers Symposium And San Antonio Breast Cancer Symposium.
| S-EPMC5821246 | biostudies-literature
Unknown Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting.
| S-EPMC10401827 | biostudies-literature
Unknown Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting.
| S-EPMC10463662 | biostudies-literature
Unknown BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting.
| S-EPMC10385907 | biostudies-literature
Unknown Correction to: Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting.
| S-EPMC10546715 | biostudies-literature
Unknown Scientific Advancements in Drug Development and Trials for Urothelial Carcinoma: Insights From the 2023 ASCOGU Cancers Symposium.
| S-EPMC10676780 | biostudies-literature
Unknown Neues aus der Urologie von GU-ASCO, ASCO und EAU
| S-EPMC7651824 | biostudies-literature